# Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease

> **NCT07085039** · PHASE2 · RECRUITING · sponsor: **University of Pennsylvania** · enrollment: 14 (estimated)

## Conditions studied

- Castleman's Disease (CD)
- Idiopathic Multicentric Castleman's Disease

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT07085039
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085039, "Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT07085039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*